肠道微生物群在抗肿瘤免疫和免疫治疗中的潜在机制和靶向策略。
Potential mechanisms and targeting strategies of the gut microbiota in antitumor immunity and immunotherapy.
机构信息
Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China.
Department of Hepato-Pancreato-Biliary & Gastric Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
出版信息
Immun Inflamm Dis. 2024 Jul;12(7):e1263. doi: 10.1002/iid3.1263.
BACKGROUND
Immunotherapies, notably immune checkpoints inhibitors that target programmed death 1/programmed death ligand 1(PD-1/PD-L1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), had profoundly changed the way advanced and metastatic cancers are treated and dramatically improved overall and progression-free survival.
AIMS
This review article aimed to explore the underlying molecular mechanisms by which the gut microbiota affects antitumor immunity and the efficacy of cancer immunotherapy.
METHODS
We summarized the latest knowledge supporting the associations among the gut microbiota, antitumor immunity, and immunotherapy. Moreover, we disscussed the therapeutic strategy for improving immunotherapy efficacy by modulating gut microbiota in cancer treatment.
RESULTS
The potential molecular mechanisms underlying these associations are explained in terms of four aspects: immunomodulation, molecular mimicry, mamps, and microbial metabolites.
CONCLUSION
The gut microbiota significantly impacts antitumor immunity and alters the effectiveness of cancer immunotherapy.
背景
免疫疗法，特别是针对程序性死亡受体 1/程序性死亡配体 1（PD-1/PD-L1）和细胞毒性 T 淋巴细胞相关抗原 4（CTLA-4）的免疫检查点抑制剂，极大地改变了晚期和转移性癌症的治疗方式，并显著提高了总体生存率和无进展生存率。
目的
本文旨在探讨肠道微生物群影响抗肿瘤免疫和癌症免疫治疗疗效的潜在分子机制。
方法
我们总结了支持肠道微生物群、抗肿瘤免疫和免疫治疗之间关联的最新知识。此外，我们讨论了通过调节癌症治疗中的肠道微生物群来改善免疫治疗疗效的治疗策略。
结果
这些关联的潜在分子机制可以从四个方面来解释：免疫调节、分子模拟、模式识别分子和微生物代谢物。
结论
肠道微生物群显著影响抗肿瘤免疫，并改变癌症免疫治疗的效果。
Zotero 插件